Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | USP18 | Q9UMW8 | 2/20 | 0.49 |
| ▸ | UCHL5 | Q9Y5K5 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14880394 | 1.00 | CYP1A2 (0.56) | CYP1A2EGFRUSP18UCHL5HSP90AA1 | |
| SCHEMBL15940308 | 0.89 | CYP1A2 (0.69) | CYP1A2EGFRMAPTMEN1ALDH1A1 | |
| SCHEMBL15940309 | 0.89 | CYP1A2 (0.69) | CYP1A2EGFRMAPTMEN1ALDH1A1 | |
| SCHEMBL14880647 | 0.84 | USP18 (0.52) | EGFRUSP18UCHL5HSP90AA1USP2 | |
| SCHEMBL14880648 | 0.84 | USP18 (0.52) | EGFRUSP18UCHL5HSP90AA1USP2 | |
| SCHEMBL14797847 | 0.80 | USP18 (0.67) | USP18UCHL5HSP90AA1USP2MAOB | |
| SCHEMBL14797848 | 0.80 | USP18 (0.67) | USP18UCHL5HSP90AA1USP2MAOB | |
| SCHEMBL17693072 | 0.79 | CYP1A2 (0.70) | CYP1A2EGFRMAOBMAPTRAB9A | |
| SCHEMBL15561397 | 0.79 | CYP1A2 (0.70) | CYP1A2EGFRMAOBMAPTRAB9A | |
| SCHEMBL15561399 | 0.79 | CYP1A2 (0.70) | CYP1A2EGFRMAOBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780326-B1 | METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY | VIVOLUX AB (SE) | 2018-12-26 | — | — | EP | disclosed |
| US-9221761-B2 | Method for inhibition of deubiquitinating activity | VIVOLUX AB (SE) | 2015-12-29 | — | — | US | disclosed |
| EP-2780326-A1 | METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY | Vivolux Ab (SE) | 2014-09-24 | — | — | EP | disclosed |
| US-20140228354-A1 | Method for Inhibition of Deubiquitinating Activity | VIVOLUX AB (SE) | 2014-08-14 | — | — | US | disclosed |
| WO-2013058691-A1 | METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY | VIVOLUX AB (SE) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228354-A1 | Method for Inhibition of Deubiquitinating Activity | USP19, USP1, USP18 | CYP1A2 2892/4885EGFR 2652/4885USP18 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.